Chenghu Huang

Chenghu Huang


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2025 in Diabetes, Metabolic Syndrome and Obesity
Verified
Journal Article
Open access
PDF file
ZLZixuan Li
Zixuan Li
ZHZhoubo Han
Zhoubo Han
RSRong Sun
Rong Sun
XXXiuping Xuan
Xiuping Xuan
CHChenghu Huang
Chenghu Huang
Purpose: To investigate the long-term efficacy and changing trajectories of glucagon-like peptide-1 receptor agonists (GLP-1RAs) among patients with type 2 diabetes. Methods: The PubMed, Embase and Cochrane Library databases were searched up to March 2024 to identify randomized controlled trials that assessed the efficacy of GLP-1RAs compared with placebo. To further explore the long-term trajectories of GLP-1RAs, we also conducted subgroup analyses of the placebo-subtracted groups based on the follow-up periods: 12– 18 weeks, 24– 30 weeks, 48– 56 weeks, 68– 78 weeks and ≥ 104 weeks. Results: Fifty-five trials involving 18,876 participants were included in this meta-analysis. GLP-1RAs significantly improved HbA1c levels, body weight, fasting plasma glucose (FPG), systolic blood pressure, and serum lipid levels. GLP-1RAs continuously reduced HbA1c and FPG for at least 104 weeks, with the largest reductions observed at 12– 18 weeks (versus placebo, WMD − 0.99 [− 1.09, − 0.89], P < 0.001; − 1.56 [− 1.82. − 1.29], P < 0.001, respectively). However, the reductions in HbA1c and FPG at ≥ 104 weeks were approximately 0.36% and 0.47 mmol/L less than the reductions at 12– 18 weeks, respectively. With respect to weight loss, the optimal effect was observed at 24– 30 weeks (WMD − 2.42 [− 2.90, − 1.95], P < 0.001), followed by a plateau period. In addition, GLP-1RAs were associated with a greater risk of hypoglycemia and gastrointestinal adverse events. Conclusion: GLP-1RAs are recommended for long-term treatment of patients with type 2 diabetes due to the persistent improvement in glycemic control and weight loss. However, it is important to account for the weakening effects after 2 years.

15 October 2026 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
ZZZiyi Zhang
Ziyi Zhang
CPChangwei Peng
Changwei Peng
HPHong Peng
Hong Peng
YZYuanxia Zhu
Yuanxia Zhu
CHChenghu Huang
Chenghu Huang
LRLi Rong
Li Rong
Background: Hypertriglyceridemic acute pancreatitis (HTG-AP) is accompanied by significant metabolic abnormalities, but few studies have investigated whether a composite measure of this metabolic burden is associated with severe acute pancreatitis (SAP). The metabolic score for insulin resistance (METS-IR), derived from fasting glucose, high-density lipoprotein cholesterol, triglycerides, and body mass index, can be calculated from routinely available clinical data without requiring an insulin assay. However, its association with SAP in HTG-AP remains poorly characterized. Objective: This study investigates the association between admission METS-IR and SAP in patients with HTG-AP and assesses the robustness of this association through subgroup and sensitivity analyses. Methods: We retrospectively assembled a single-center cohort of 456 adults admitted with HTG-AP between January 2019 and July 2025. Logistic regression evaluated METS-IR as a continuous exposure and in quartiles. Restricted cubic splines, subgroup analyses, and sensitivity analyses were performed. Exploratory ROC analyses compared apparent discrimination with TyG, TyG-BMI, and BISAP. Results: SAP occurred in 78 of 456 patients (17.1%). Median METS-IR was 69.99 (IQR, 61.92–83.67) in the SAP group and 58.18 (IQR, 51.47–66.46) in the non-SAP group. In Model 3, each one-point increase in METS-IR was associated with higher odds of SAP (OR, 1.06; 95% CI, 1.04–1.08). After additional adjustment for TG, TG/HDL-C, and TyG, the estimate was attenuated (OR, 1.03; 95% CI, 0.997–1.064; P = 0.073). Apparent AUCs were 0.730 for METS-IR, 0.720 for TyG, and 0.758 for BISAP; neither paired comparison showed a statistically significant difference. In the three-category analysis, the METS-IR association was stronger for SAP vs. MAP than for MSAP vs. MAP. Conclusion: Higher admission METS-IR was independently associated with higher odds of SAP in patients with HTG-AP. METS-IR may provide a readily available measure of metabolic burden for early clinical assessment of patients with HTG-AP, although its clinical utility requires confirmation in prospective multicenter studies.

1 January 2025 in Journal of Diabetes Research
Verified
Journal Article
Open access
ZLZixuan Li
Zixuan Li
RSRong Sun
Rong Sun
THTiantian Huang
Tiantian Huang
ZHZhoubo Han
Zhoubo Han
XXXiuping Xuan
Xiuping Xuan
CHChenghu Huang
Chenghu Huang
Background: Diabetes mellitus (DM) and cardiovascular disease (CVD) are interconnected conditions that significantly contribute to global mortality, yet their bidirectional relationship and combined mortality impact remain underexplored. Methods: Utilizing data from the NHANES 2005–2018 cohort ( N = 24,934), we categorized participants aged ≥ 35 years into four groups: nondiabetic/non–pre‐existing CVD, diabetic/non–pre‐existing CVD, nondiabetic/pre‐existing CVD, and diabetic/pre‐existing CVD. Propensity score matching (PSM) and causal mediation analysis were employed to assess independent and synergistic mortality risks. Results: Over a mean follow‐up of 7.37 years, diabetic/pre‐existing CVD participants exhibited the highest mortality rates (61.37 all‐cause and 23.88 cardiovascular deaths per 1000 person‐years). Diabetes alone increased all‐cause mortality by 34% (HR = 1.34, 95% CI = 1.22–1.47) and cardiovascular mortality by 32% (HR = 1.32, 1.10–1.58), while pre‐existing CVD alone increased risks by 72% (HR = 1.72, 1.56–1.89) and 142% (HR = 2.42, 2.05–2.87), respectively. Comorbid diabetes/pre‐existing CVD synergistically elevated all‐cause mortality by 142% (HR = 2.42, 2.19–2.68) and cardiovascular mortality by 237% (HR = 3.37, 2.83–4.02). Although no statistically significant multiplicative interaction was observed, additive interaction metrics between diabetes and pre‐existing CVD on mortality risks revealed a stronger synergistic effect on cardiovascular mortality (RERI = 0.64–1.17, AP = 12.01 % –23.82%) than on all‐cause mortality (RERI = 0.39–0.75, AP = 9.26 % –18.73%). Mediation analysis demonstrated bidirectional effects: Diabetes mediated 6.82% of all‐cause and 4.17% of cardiovascular mortality in pre‐existing CVD patients, while pre‐existing CVD mediated 5.47% and 7.87% in diabetic individuals. Conclusions: Diabetes and pre‐existing CVD independently and synergistically increase mortality risks, with additive interactions particularly pronounced for cardiovascular mortality. The bidirectional mediation effects highlight the need for integrated management strategies to mitigate the compounded mortality burden.